Haemonetics Corporation (HAE) was Reiterated by The Benchmark Company to “Hold” according to the research note released today. The brokerage firm has raised the Price Target to $ 32 from a previous price target of $28 . The Benchmark Company advised their investors in a research report released on Aug 2, 2016.
Many Wall Street Analysts have commented on Haemonetics Corporation. Company shares were Reiterated by Jefferies on Aug 2, 2016 to “Buy”, Firm has raised the Price Target to $ 40 from a previous price target of $32 .Haemonetics Corporation was Upgraded by Goldman to ” Neutral” on May 16, 2016. Shares were Reiterated by The Benchmark Company on May 11, 2016 to “Hold” and Lowered the Price Target to $ 28 from a previous price target of $35 .
On the company’s financial health, Haemonetics Corporation reported $0.25 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Aug 1, 2016. Analyst had a consensus of $0.29. The company had revenue of $210.00 million for the quarter, compared to analysts expectations of $205.41 million. The company’s revenue was down -1.6 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.35 EPS.
Haemonetics Corporation opened for trading at $29.77 and hit $30.41 on the upside on Friday, eventually ending the session at $30.32, with a gain of 1.61% or 0.48 points. The heightened volatility saw the trading volume jump to 5,25,597 shares. Company has a market cap of $1,548 M.
In a different news, on Oct 28, 2015, Sandra Jesse (EVP and Chief Legal Officer) sold 778 shares at $32.13 per share price. According to the SEC, on Oct 28, 2015, Byron Selman (President, Global Markets) sold 344 shares at $32.13 per share price. On Oct 28, 2015, Jonathan White (Chief Science and Technology) sold 319 shares at $32.13 per share price, according to the Form-4 filing with the securities and exchange commission.
Haemonetics Corporation is a healthcare company which provides blood management solutions to its customers. The Company’s portfolio of integrated devices information management and consulting services offers blood management solutions for each facet of the blood supply chain. It serves three customer segments: manufacturers of plasma derived pharmaceuticals blood collectors and hospitals. Its multiple product lines under four global product categories include Plasma Blood Center Hospital and Software Solutions. Its Plasma includes plasma collection devices and disposables. Its Blood Center includes blood collection and processing devices and disposables. Its Hospital includes surgical blood salvage and blood demand diagnostic devices and disposables. Its Software Solutions includes information technology platforms and consulting services provided to all three markets. It operates in North America Plasma North America Blood Center and Hospital Europe Asia Pacific and Japan.